Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A2/ PAF Acetylhydrolase
- 18 February 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 108 (4), 469-477
- https://doi.org/10.1161/circresaha.110.228742
Abstract
Rationale: The phospholipid platelet-activating factor (PAF) stimulates all cells of the innate immune system and numerous cardiovascular cells. A single enzyme (plasma PAF acetylhydrolase [PAF-AH] or lipoprotein-associated phospholipase [Lp-PL]A2) in plasma hydrolyzes PAF, but significant controversy exists whether its action is pro- or antiinflammatory and accordingly whether its inhibition will slow cardiovascular disease. Objective: We sought to define how PAF and related short-chain oxidized phospholipids turnover in vivo and the role of PAF acetylhydrolase/Lp-PLA2 in this process. Methods and Results: [3H-acetyl]PAF was hydrolyzed by murine or human plasma (t1/2, 3 and 7 minutes, respectively), but injected [3H-acetyl]PAF disappeared from murine circulation more quickly (t1/2, 3H]PAF clearance was unchanged in PAF receptor−/− animals, or over the first 2 half-lives in PAF-AH−/− animals. [3H]PAF turnover was reduced by coinjecting excess unlabeled PAF or an oxidatively truncated phospholipid, and [3H]PAF clearance was slowed in hyperlipidemic apolipoprotein (apo)E−/− mice with excess circulating oxidatively truncated phospholipids. [3H]PAF, fluorescent NBD-PAF, or fluorescent oxidatively truncated phospholipid were primarily accumulated by liver and lung, and were transported into endothelium as intact phospholipids through a common mechanism involving TMEM30a. Conclusions: Circulating PAF and oxidized phospholipids are continually and rapidly cleared, and hence continually and rapidly produced. Saturable PAF receptor–independent transport, rather than just intravascular hydrolysis, controls circulating inflammatory and proapoptotic oxidized phospholipid mediators. Intravascular PAF has access to intracellular compartments. Inflammatory and proapoptotic phospholipids may accumulate in the circulation as transport is overwhelmed by substrates in hyperlipidemia.Keywords
This publication has 59 references indexed in Scilit:
- Human TMEM30a Promotes Uptake of Antitumor and Bioactive Choline Phospholipids into Mammalian CellsThe Journal of Immunology, 2011
- Dual Roles of Endogenous Platelet-Activating Factor Acetylhydrolase in a Murine Model of Necrotizing EnterocolitisPediatric Research, 2010
- Chronic Alcohol Exposure Increases Circulating Bioactive Oxidized PhospholipidsOnline Journal of Public Health Informatics, 2010
- PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A 2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European AncestryCirculation, 2010
- Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density LipoproteinPublished by Elsevier BV ,2008
- Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotypeNature Medicine, 2007
- Cytotoxic Phospholipid Oxidation Products: CELL DEATH FROM MITOCHONDRIAL DAMAGE AND THE INTRINSIC CASPASE CASCADEPublished by Elsevier BV ,2007
- Binding of platelet activating factor to albuminBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipidLife Sciences, 1981
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959